key: cord-1030902-fifo7p3q authors: Maeda, Hajime; Haneda, Kentaro; Honda, Yoshinobu title: Parainfluenza virus type 3 outbreak in a neonatal intensive care unit date: 2017-11-29 journal: Pediatr Int DOI: 10.1111/ped.13389 sha: 463dc0b933a7565e628b69a1550bcd77d177805b doc_id: 1030902 cord_uid: fifo7p3q Parainfluenza virus (PIV) is a respiratory pathogen in young children and is second only to the respiratory syncytial virus (RSV) as a cause of lower respiratory tract infection. PIV type 3 (PIV3) is the most severe. Herein we describe an outbreak of PIV3 in three infants in a neonatal intensive care unit. They were diagnosed on virus culture from pharyngeal swabs. We prevented the spread of the virus using standard infection control procedures and isolation of the symptomatic infants. One infant had severe chronic lung disease and was complicated with recurrent wheezing for a long time. Because RSV and PIV have many structural, pathogenic, epidemiologic, and clinical similarities, we speculate that PIV infection causes recurrent wheezing, as observed with RSV infection. Therefore, physicians must consider recurrent wheezing at the time of treatment of PIV infection early in life. Human parainfluenza virus (PIV) types 1, 2, 3, and 4 are primarily known as respiratory pathogens in young children. 1 PIV causes >30% of all acute respiratory infections in infants and children and is second only to respiratory syncytial virus (RSV) as a cause of lower respiratory tract infection (LRTI) in young children. 2 Outbreaks of PIV type 3 (PIV3) infection occur annually, mainly in the spring and summer, and PIV3 is more severe than other types of PIV, especially in infants. 1 Nevertheless, PIV3 outbreak in a neonatal intensive care unit (NICU) is less frequently reported than RSV. We experienced an outbreak of PIV3 in three infants in the NICU at Iwaki Kyoritsu Hospital. One infant with severe chronic lung disease (CLD) also had recurrent wheezing. This report will be valuable because it is the first to describe severe CLD in infants complicated with recurrent wheezing after PIV3 outbreak in the NICU. Patient demographics and clinical presentation are given in Table 1 . The index patient was a 114-day-old female infant from a set of fraternal twins (with dichorionic diamniotic placenta on histopathology). She had been delivered at 28 weeks of gestation via emergency cesarean section due to chorioamnionitis. Birthweight was 974 g and Apgar scores was 6 and 7 at 1 and 5 min, respectively. Shortly after birth, she was intubated and ventilated for respiratory distress syndrome (RDS); she remained on a ventilator for 37 days from birth and required nasal continuous positive airway pressure (NCPAP) until day 75. She was diagnosed with CLD at 36 weeks' post-menstrual age (PMA). She did not require oxygen after being taken off NCPAP and developed wheezing. Apnea, fever, and cough were seen on day 114 (July 24). PIV3 was detected on virus culture, and pulmonary infiltrates were seen on chest radiography. The patient also required NCPAP or oxygen for another 13 days. The duration of respiratory symptoms was 17 days. She was discharged on day 136. The patient had recurrent wheezing after discharge, which reappeared with the common cold until 1 year of age. Patient 2 was a 115-day-old male infant, the sibling of patient 1. He had also been delivered at 28 weeks of gestation. His birthweight was 970 g and his Apgar score was 6 and 7 at 1 and 5 min, respectively. Shortly after birth, he was intubated and ventilated for RDS; he remained on a ventilator for 8 days and required NCPAP until day 71. He was diagnosed with CLD at 36 weeks' PMA. He developed apnea and cough on day 115, on July 25, 1 day after patient 1. PIV3 was detected on virus culture, but chest radiograph was unchanged. He did not require respiratory support such as NCPAP or oxygen. The duration of the respiratory symptoms was 7 days. He was discharged on day 136. He had no complications such as recurrent wheezing after discharge. Patient 3 was a 40-day-old male infant. He had been delivered at 35 weeks of gestation via emergency cesarean section because of total placenta previa bleeding. Birthweight was 2,440 g, and Apgar score was 7 and 8 at 1 and 5 min, respectively. After birth, he was intubated and ventilated for RDS for 2 days. He was not diagnosed with CLD at 36 weeks' PMA. He developed a cough on day 40, on July 29, 5 days after patient 1. PIV3 was detected on virus culture, but chest radiograph was unchanged. He did not require respiratory support such as NCPAP or oxygen. The duration of respiratory symptoms was 6 days. He had complications of wheezing, but the symptoms were self-limited. He was discharged on day 70. He did not have recurrent wheezing after discharge. Between July and August 2013, an outbreak of PIV3 occurred in three infants in the present facility. Subsequently, no staff or visitor had clinical symptoms. On July 24, four infants were housed in the NICU and six in the growing care unit. After the index case, all symptomatic infants (patients 1-3) were screened for the viral antigen using pharyngeal swabs. In the outbreak setting, we reinforced standard infection control procedures, including handwashing; use of gowns, gloves, and masks; and cohort placement on July 25, 1 day after patient 1 developed symptoms. On July 31, after establishing a night nurse shift system, specific nurses cared for patients in the isolation room. We transferred the symptomatic infants (patients 1-3) to the isolation room to isolate them from asymptomatic infants, thereby preventing the spread of the virus. Symptomatic infants (patients 1-3) were screened using nasopharyngeal swabs and kits for rapidly testing for RSV, adenovirus, and influenza virus. They were also screened on virus culture for the viral antigen using pharyngeal swabs. All viral antigen tests were negative. PIV3 was isolated and identified in patients 1-3. PIV3 was isolated using African green monkey kidney (Vero) cells and identified using indirect immunofluorescence (Anti-Parainfluenza 3 Blend Antibody, clones 240/12D, 260/10B, MAB855-3; Merck Millipore, Darmstadt, Germany; and Polyclonal Rabbit Anti-Mouse Immunogloblins/FITC, FITC, Immunofluorescence, F0232; Agilent Technologies, Santa Clara, CA, USA). Human parainfluenza virus type 3 outbreak in NICU is rare despite the prevalence of common pathogens in pediatric LRTI. Conversely, RSV is the most common pathogen of pediatric LRTI; consequently, RSV outbreaks in the NICU are more common than PIV3. These differences might be associated with the method and kit for rapid testing for the virus antigen. There is no method and kit for rapidly testing for PIV3; therefore, detection of PIV3 might be more difficult. In previous reports of PIV3 outbreak in NICU, 2-8 virus culture and polymerase chain reaction (PCR) were used. PCR is a sensitive and rapid method for detecting virus, but they cannot always be performed at all facilities. Therefore, we chose virus culture for testing respiratory infections of unknown origin and detected PIV3. PCR for multiple respiratory viruses has been widely implemented, and its application is increasing because of the better sensitivity and rapid turnaround time in the clinical care setting. In addition, it is easier to simultaneously diagnose multiple viruses in patients with co-infection. The more we perform PCR for multiple respiratory viruses and virus culture for respiratory infections of unknown origin in the NICU, the more frequently we might detect respiratory viruses, such as PIV, rhinovirus, coronavirus, Coxsackie virus, and echovirus. Most PIV infections are self-limited, but mortality and severe outbreaks in NICU that require ventilation have been reported in infants with severe comorbidities, 2-8 but no case of recurrent wheezing after discharge has been reported ( Table 2) . Particularly, in the present patients, the index case of CLD was the most severe. The index patient, ventilated for a long time with CLD, required supportive treatment after PIV3 infection and had recurrent wheezing after discharge for a long time. RSV has frequently been associated with recurrent wheezing in preterm infants. 1 In terms of PIV, Welliver et al. reported a rate of 85% and of 10% for recurrent wheezing episodes following PIV bronchiolitis and upper respiratory tract infection, respectively, 9 and LRTI may predispose to episodes of broncho-constriction on subsequent exposure. RSV and PIV have many structural, pathogenic, epidemiologic, and clinical similarities. 1 Therefore, the clinical course of PIV might be similar to that of RSV in many aspects. Preterm infants with bronchopulmonary dysplasia present with chronic airway obstruction defined as recurrent episodes of wheezing and decreased lung function tests; and in some of these infants, obstructive lung disease persists into adulthood. 10 We speculate that the index case of severe CLD and PIV3 infection in a preterm infant early after birth worsened lung function, prompting the requirement for NCPAP. PIV3 infection might cause recurrent wheezing as observed in RSV infection, but it is not clear whether the present case of recurrent wheezing was caused by this PIV3 infection alone. We should consider PIV3 as one of the pathogens of respiratory infection of unknown origin in the NICU, and provide attention to severity if preterm infants with CLD develop PIV3 infection. The authors declare no conflict of interest. Respiratory syncytial virus and parainfluenza virus A simultaneous outbreak of respiratory syncytial virus and parainfluenza virus type 3 in a newborn nursery Outbreak of parainfluenza virus type 3 in a neonatal nursery Outbreak of parainfluenza virus type 3 in an intermediate care neonatal nursery Parainfluenza type 3 viral outbreak in a neonatal nursery Outbreak of parainfluenza virus type 3 in a neonatal intensive care unit Morbidity of parainfluenza 3 outbreak in preterm infants in a neonatal unit Parainfluenza virus type 3 outbreak in a neonatal nursery Parainfluenza virus bronchiolitis. Epidemiology and pathogenesis Preterm birth and respiratory disease in later life H.M. drafted the manuscript; K.H. reviewed the manuscript; Y.H. critically reviewed the manuscript and supervised the whole study process. All authors read and approved the final manuscript.